Raveen Syan, MD, FPMRS, previews the 2025 Urology on the Beach conference
December 19th 2024"What's unique about our conference is the focus is not on just showcasing what our institute has to offer; the real focus is on networking and collaborating with the top institutes in the nation," says Raveen Syan, MD, FPMRS.
Eric Jonasch, MD, on phase 1/2 trial of 177Lu-girentuximab combination in ccRCC
December 18th 2024“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet alone,” says Eric Jonasch, MD.
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
December 18th 2024“What we've been working on is a giant 30,000 patient database study using the National Cancer Database to see exactly what the rates are of upstaging and downstaging for these larger kidney tumors,” says Taylor Goodstein, MD.
Chad Ellimoottil, MD, on the ‘positive momentum’ to extend telehealth flexibilities
December 16th 2024"I think that there's been a lot of positive momentum to continue coverage for telehealth without geographic restrictions, to continue coverage for phone calls, but there's still some uncertainty as to whether or not that's going to be passed, even though there is a lot of optimism for it," says Chad Ellimoottil, MD, MS.
Tobias Nordström, MD, on follow-up data from the STHLM3 trial
December 11th 2024“We can now see that we can find a proportion of those men that have an elevated STHLM3 tests that actually have a quite substantial risk of biochemical recurrence after the radical prostatectomy,” says Tobias Nordström, MD, PhD.
Juan Andino, MD, highlights SUO session on telehealth in urology
December 10th 2024“Without Congressional action, all the progress that has been made—the new normal, so to speak—that patients, physicians, and providers alike have become used to, is at risk of potentially going back to pre-pandemic, 2019 levels,” says Juan J. Andino, MD, MBA.
Vikram Narayan, MD, on cystectomy outcomes in nadofaragene-treated patients
December 9th 2024“Overall, the take-home message is that in patients with BCG-unresponsive non–muscle-invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients,” says Vikram M. Narayan, MD.